Overview

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the progression-free survival (PFS) of Chemotherapy combined with SHR-1316 in patients with advanced esophageal squamous cell cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Camptothecin
Fluorouracil
Irinotecan